First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: Results from the randomized phase III MONALEESA-7 trial

被引：0
|
作者：
Tripathy, Debu
Sohn, Joohyuk
Im, Seock-Ah
Colleoni, Marco
Franke, Fabio
Bardia, Aditya
Harbeck, Nadia
Hurvitz, Sara
Chow, Louis
Lee, Keun Seok
Campos-Gomez, Saul
Vazquez, Rafael Villanueva
Jung, Kyung Hae
Carlson, Gary
Hughes, Gareth
Diaz-Padilla, Ivan
Germa, Caroline
Hirawat, Samit
Lu, Yen-Shen
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Yonsei Univ Hlth Syst, Severance Hosp, Seoul, South Korea
[3] Seoul Natl Univ, Coll Med, Seoul, South Korea
[4] Ist Europeo Oncol, Unita Ric Senol Med, Milan, Italy
[5] CACONIjui, Hosp Caridade Ijui, Ijui, RS, Brazil
[6] Havard Med Sch, Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[7] Univ Munich LMU, Breast Ctr, Munich, Germany
[8] UCLA Jonsson Comprehens Canc Ctr, Los Angeles, CA USA
[9] Org Oncol & Translat Res, Hong Kong, Hong Kong, Peoples R China
[10] Res Inst & Hosp, Natl Canc Ctr, Goyang, South Korea
[11] Inst Seguridad Social Estado Mexico & Municipios, Ctr Oncol Estatal, Toluca, Mexico
[12] Hosp Moises Broggi, Inst Catala Oncol, Barcelona, Spain
[13] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
[14] Nova Pharmaceut Corp, E Hanover, NJ USA
[15] Novartis Pharma AG, Basel, Switzerland
[16] Natl Taiwan Univ Hosp, Taipei, Taiwan
来源：
CANCER RESEARCH | 2018年 / 78卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
GS2-05
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Ribociclib with a non-steroidal aromatase inhibitor and goserelin in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: MONALEESA-7 age subgroup analysis
    Tripathy, D.
    Campos-Gomez, S.
    Lu, Y-S
    Franke, F.
    Bardia, A.
    Wheatley-Price, P.
    Cruz, F. M.
    Hegg, R.
    Cardoso, F.
    Gaur, A.
    Kong, O.
    Diaz-Padilla, I.
    Miller, M.
    Hurvitz, S.
    CANCER RESEARCH, 2019, 79 (04)
  • [2] Ribociclib (RIB) plus non-steroidal aromatase inhibitor (NSAI) plus goserelin in premenopausal Asian women with hormone-receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): Results from the randomized phase III MONALEESA-7 study
    Im, S-A.
    Sohn, J.
    Tripathy, D.
    Chow, L.
    Lee, K. S.
    Jung, K. H.
    Babu, G.
    Im, Y-H.
    El Saghir, N.
    Liu, M-C.
    Diaz-Padilla, I.
    Alam, J.
    Kong, O.
    Miller, M.
    Lu, Y-S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [3] Tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) with ribociclib (RIB) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-7 subgroup analysis
    Bardia, A.
    Campos-Gomez, S.
    Hurvitz, S. A.
    Lu, Y-S.
    Im, S-A.
    Franke, F.
    Chow, L.
    Wheatley-Price, P.
    Melo Cruz, F.
    Alam, J.
    Kong, O.
    Diaz-Padilla, I.
    Miller, M.
    Tripathy, D.
    ANNALS OF ONCOLOGY, 2018, 29 : 106 - +
  • [4] Ribociclib with endocrine therapy for premenopausal patients with hormone receptor -positive, HER2-negative advanced breast cancer: Biomarker analyses from the phase III randomized MONALEESA-7 trial
    Bardia, A.
    Colleoni, M.
    Campos-Gomez, S.
    Jung, K. H.
    Wheatley-Price, P.
    Kuemmel, S.
    Srimuninnimit, V.
    Taylor, D.
    Im, Y-H
    Hughes, G.
    Diaz-Padilla, I.
    Miller, M.
    Su, F.
    Tripathy, D.
    CANCER RESEARCH, 2019, 79 (04)
  • [5] Ribociclib (RIB) plus tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): additional results from the MONALEESA-7 trial
    Harbeck, N.
    Vazquez, R. Villanueva
    Tripathy, D.
    Lu, Y.
    De Laurentiis, M.
    Kuemmel, S.
    Taylor, D.
    Bardia, A.
    Hurvitz, S.
    Chow, L.
    Im, S.
    Franke, F.
    Hughes, G.
    Miller, M.
    Kong, O.
    Chandiwana, D.
    Colleoni, M.
    EUROPEAN JOURNAL OF CANCER, 2018, 92 : S3 - S3
  • [6] Ribociclib (RIB) plus tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) who received prior chemotherapy (CT): MONALEESA-7 subgroup analysis
    Hurvitz, Sara A.
    Wheatley-Price, Paul
    Tripathy, Debu
    Lu, Yen-Shen
    Chow, Louis
    Bachelot, Thomas Denis
    Hegg, Roberto
    Chia, Stephen K. L.
    Yardley, Denise A.
    Kong, Oliver
    Alam, Jahangir
    Diaz-Padilla, Ivan
    Baeck, Johan
    Bardia, Aditya
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] Ribociclib (RIB) plus tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal patients (pts) with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-7 patient-reported outcomes (PROs)
    Harbeck, N.
    Villanueva, R.
    Franke, F.
    Babu, G.
    Wheatley-Price, P.
    Im, Y-H.
    Altundag, K.
    Lanoue, B.
    Alam, J.
    Chandiwana, D.
    Colleoni, M.
    ANNALS OF ONCOLOGY, 2018, 29
  • [8] Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer
    Hortobagyi, G. N.
    Stemmer, S. M.
    Burris, H. A.
    Yap, Y. S.
    Sonke, C. S.
    Paluch-Shimon, S.
    Campone, M.
    Petrakova, K.
    Blackwell, K. L.
    Winer, E. P.
    Janni, W.
    Verma, S.
    Conte, P.
    Arteaga, C. L.
    Cameron, D. A.
    Mondal, S.
    Su, F.
    Miller, M.
    Elmeliegy, M.
    Germa, C.
    O'Shaughnessy, J.
    ANNALS OF ONCOLOGY, 2018, 29 (07) : 1541 - 1547
  • [9] Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7)
    Harbeck, Nadia
    Franke, Fabio
    Villanueva-Vazquez, Rafael
    Lu, Yen-Shen
    Tripathy, Debu
    Chow, Louis
    Babu, Govind K.
    Im, Young-Hyuck
    Chandiwana, David
    Gaur, Anil
    Lanoue, Brad
    Rodriguez-Lorenc, Karen
    Bardia, Aditya
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [10] Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib plus letrozole in hormone receptor-positive (HR+), HER2-negative (HER2-), advanced breast cancer (ABC).
    Hortobagyi, Gabriel N.
    Stemmer, Salomon M.
    Burris, Howard A.
    Yap, Yoon Sim
    Sonke, Gabe S.
    Paluch-Shimon, Shani
    Campone, Mario
    Petrakova, Katarina
    Blackwell, Kimberly L.
    Winer, Eric P.
    Janni, Wolfgang
    Verma, Sunil
    Conte, Pier Franco
    Arteaga, Carlos L.
    Cameron, David A.
    Xuan, Fengjuan
    Miller, Michelle Kristine
    Germa, Caroline
    Hirawat, Samit
    O'Shaughnessy, Joyce
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345